Humacyte

Manufacturing · North Carolina, United States · 51-200 Employees

View Company Info for Free

Overview

Headquarters

2525 E North Carolina Hwy 54, Durham, No...

Phone Number

(919) 313-9633

Revenue

<$5 Million

Stock Symbol

HUMA

Industry

Manufacturing Business Services Research & Development Medical Devices & Equipment
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1

About Humacyte

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Explore more
Humacyte's Social MediaPopular SearchesHUMACYTE IncHumacyteHumacyte Global IncHumacyte ExpandsSIC Code 38,384NAICS Code 33,339Ticker NASDAQ: HUMAShow more

Humacyte Org Chart

PhoneEmail
AP
United States flag for contact location.

Chief Medical Officer

PhoneEmail
SO
United States flag for contact location.

Chief People Officer

PhoneEmail
Shamik Parikh, Chief Medical Officer at Humacyte
United States flag for contact location.

Chief Medical Officer

PhoneEmail

PhoneEmail
Get the full picture
Sign in to uncover key details.
TR
United States flag for contact location.

Chief Surgical Officer

PhoneEmail

PhoneEmail
Get the full picture
Sign in to uncover key details.

Is Humacyte your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Recommended Actions

Compare Similar Companies to Humacyte

Compare insights from companies similar to Humacyte, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.

Company Name

Revenue

Number of Employees

Type

Funding

Founded In

Top Executive

Humacyte

<$5M
51-200
Public
$587.9M
2004
AP
Alison PilgrimChief Medical Officer
$105.7M
201-500
Private
$1.2B
2017
$80M
201-500
Private
$212.3M
2015
PM
Peter MillerVice President, Research & Development
$34.4M
51-200
Public
$396.7M
2006
Robert Spignesi, President & Chief Executive Officer at Rapid Micro Biosystems
Robert SpignesiPresident & CEO
$23.9M
51-200
Private
-
2004
$23.1M
51-200
Private
<$5M
2000
$14M
51-200
Private
<$5M
1985
Illustration of an envelope

Company Profile Activity

i

Among all Manufacturing companies

Low Activity

High Activity

Activity Insights

Humacyte is experiencing very low activity levels compared to other companies in the Manufacturing sector.

What does this means?

Humacyte is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Humacyte.

Humacyte financials insights

Gather financial insights about Humacyte, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.

2015

Series B

$150M

2016

Private Equity

$10M

2017

Unspecified

$14.1M

2018

Other Financing Round

$150M

2020

Debt

$2M

2021

Debt

$50M

2023

Debt

$150M

See All Humacyte's Financials Insights

Humacyte Tech Stack

A closer look at the technologies used by Humacyte

Most Recent Scoops

Open Position
Open Position
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
reported a favorable safety profile for the ATEV in the V012 trial, with total adverse events of 235 in the ATEV arm versus 287 in the AVF arm (rates of 8.9 versus 18 per patient-year), serious adverse events of 46 versus 75 (rates of 1.73 versus 4.77), and zero access-related infections in the ATEV arm compared to 3 in the AVF arm. No new or unexpected safety concerns were identified, and no study access ruptures occurred in either arm.
Project
See more scoops

Top Manufacturing Companies

Frequently Asked Questions Regarding Humacyte

What is Humacyte's stock symbol?
Humacyte's stock symbol is HUMA
What is Humacyte's official website?
Humacyte's official website is www.humacyte.com
What is Humacyte's Revenue?
Humacyte's revenue is <$5 Million
What is Humacyte's SIC code?
Humacyte's SIC: 38,384
What is Humacyte's NAICS code?
Humacyte's NAICS: 33,339
How many employees does Humacyte have?
Humacyte has 51-200 employees
What industry does Humacyte belong to?
Humacyte is in the industry of: Manufacturing, Business Services, Research & Development
What is Humacyte competition?
Humacyte top competitors include: Rapid Micro Biosystems, MatTek, SynDaver, Akoya Biosciences
What technology does Humacyte use?
Some of the popular technologies that Humacyte uses are: DocuSign, WooCommerce, WordPress.org, PHP
How do I contact Humacyte?
Humacyte contact info: Phone number: (919) 313-9633 Website: www.humacyte.com
What does Humacyte do?

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ves... sels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Read More

What are Humacyte social media links?
Humacyte Linkedin page Humacyte Twitter page Humacyte Facebook page
Who invested in Humacyte?
Humacyte has 11 investors including Reignwood Group, Access Industries, Bangkok Bank Public Company Ltd. and Credit Suisse.
Is Humacyte a public company?
Yes, Humacyte is a public company and is traded under the symbol HUMA
See more information about Humacyte

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.